{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-027247","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.925249+00:00","generated_at":"2026-05-17T06:43:42.804668+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cocrystal Pharma showcases CDI-988 at calicivirus conference, notes FDA clearance for Phase 1b challenge study","bullets":["President/co-CEO Sam Lee presented CDI-988 Phase 1 data at 9th International Calicivirus Conference (Sept 7–11) in Banff.","CDI-988 is a first oral antiviral candidate for norovirus, with broad-spectrum activity against GII.4 and GII.17.","Phase 1 showed favorable safety and tolerability, with no serious adverse events.","FDA cleared a Phase 1b human challenge study for norovirus prophylaxis/treatment; expected start before end of 2025.","CDI-988 targets a conserved region in 3CL viral proteases, designed with Cocrystal's proprietary structure-based platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-027247","json":"https://secwatch.observer/filing/0001641172-25-027247.json","markdown":"https://secwatch.observer/filing/0001641172-25-027247.md","text":"https://secwatch.observer/filing/0001641172-25-027247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225027247/0001641172-25-027247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225027247/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:43:42.804668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}